Vysis' PathVysion HER-2 Test Ships Dec. 18 At Premium To Dako's HercepTest
This article was originally published in The Gray Sheet
Executive SummaryVysis is betting that its fluorescence in situ hybridization (FISH)-based PathVysion HER-2 DNA probe kit justifies a significantly higher price than Dako's immunohistochemistry-based HercepTest.
You may also be interested in...
Aetion is also working with the US Food and Drug Administration and a number of biopharma companies on projects involving use of real-world evidence.